Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04098211

Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients

The purpose of this study is to gather information on the possible symptoms that patients with atypical neuronal ceroid lipofuscinosis type 2 (also known as aTPP1 or atypical tripeptidyl peptidase deficiency) have and how they change over time.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

About this study

This study aims characterize the natural history of atypical TPP1 deficiency patients via longitudinal multidisciplinary assessments.

Multifaceted clinical, laboratory, imaging, and diagnostic assessments will be performed at regular intervals upon enrolled aTPP1 deficiency patients, collated, and analyzed over a three-year longitudinal period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any patient with documented TPP1 enzymatic deficiency or TPP1 sequence variants
  • Onset of first symptom after 4 years of age
  • Parental provision of informed consent; child provision of assent (if necessary)

Exclusion criteria

  • Any patient with "Classical" TPP1 deficiency (onset of first symptom prior to 4 years of age)
  • Investigator assessment that patient is not suitable candidate to participate in the study

Treatment and study plan

Primary outcomes

  1. CLN2 Disease Severity Scoring

    Time frame: At baseline and every 3 months afterwards, up to 3 years

    Modified Hamburg Rating Scale. The rating scale consists of two domains (motor function, language). Within each domain, a score from 0 to 3 is assigned and overall scores are calculated by summing the domain scores for final rating of 0 (severely impaired) to 6 (normal).

  2. Electroretinogram (ERG)

    Time frame: At baseline and every 6 months afterwards, up to 3 years

    Standard ERG will be performed to measure function of cones and rods of the inner and outer photoreceptor layers which amplitudes are typically decreased in classical TPP1 deficiency.

  3. Optical Coherence Tomography (OCT)

    Time frame: At baseline and every 6 months afterwards, up to 3 years

    OCT is non-invasive, quantitative measurement of inner and outer photoreceptor layer thicknesses.

  4. Gait Assessment

    Time frame: At baseline and every 6 months afterwards, up to 3 years

    Gait assessment is acquired utilizing infrared sensors applied to participant's clothing and will include collection of walking speed, cadence, swing phase, stride length and time, walking base width, stance phase, and double limb support phase.

  5. Brain Magnetic Resonance Imaging (MRI)

    Time frame: At baseline and every 12 months afterwards, up to 3 years

    Pre/post-contrast images will be acquired to perform volumetric studies and white matter assessment.

  6. Electroencephalography (EEG)

    Time frame: At baseline and every 12 months afterwards, up to 3 years

    EEG will be obtained and analyzed for changes that may be distinctive for TPP1 deficiency. Evaluation of background activity, mild/moderate/severe slowing for age.

  7. Electroencephalography (EEG)

    Time frame: At baseline and every 12 months afterwards, up to 3 years

    EEG will be obtained and analyzed for changes that may be distinctive for TPP1 deficiency. Interictal discharges: location, focal/generalized, discharge burden.

  8. Electroencephalography (EEG)

    Time frame: At baseline and every 12 months afterwards, up to 3 years

    Seizures.

  9. Electroencephalography (EEG)

    Time frame: At baseline and every 12 months afterwards, up to 3 years

    Photoparoxysmal response: present/absent

  10. Cognitive Assessment, Wechsler Intelligence Scale for Children version 4 (WISC-IV)

    Time frame: At baseline and every 12 months afterwards, up to 3 years

    WISC-IV will generate a full scale of intelligence quotient and five primary index scores: Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory, and Processing Speed. The WAIS-IV is scored by summing the raw scores for each subtest; each raw subtest score is then converted to a scaled scored. They are then combined to create a Full Scale IQ Index score. Test takers will also be given a score on the General Ability Index (GAI).

  11. CSF Testing

    Time frame: At baseline and every 3 months afterwards, up to 3 years

    Standard laboratory testing and biobanking / storage of remaining CSF (via Ommaya if on enzyme replacement; via lumbar puncture if not on enzyme replacement)

Sponsors and collaborators

Lead sponsor

Children's Hospital of Orange County

Other

Registry information

Official study title

Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency (Neuronal Ceroid Lipofuscinosis Type 2) Patients

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Sep 23, 2019
Registry last updated
Apr 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.